CYBN.NE

Cybin Inc.

Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028

- Intravenous ("IV") CYB004 demonstrated robust and rapid-onset psychedelic effects at lower doses compared to native DMT, suggesting potential as a short-acting, scalable treatment -- Intramuscular ("IM") dosing of SPL028 produced robust, short-duration psychedelic effects in the majority of participants -- Both IV and IM routes were saf... Read More...

Cybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs

- Recently announced positive Phase 2 topline data in Major Depressive Disorder ("MDD") with 79% of patients in remission from depression after two doses of CYB003 (12mg) -- Programs supported by robust intellectual property portfolio with 40 granted patents and over 170 pending applications -- Multinational operations support scaling to ... Read More...

Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses

- Rapid, robust, and clinically significant reduction of depression symptoms observed after a single dose of CYB003, with a clear incremental benefit of a second dose -- Primary efficacy endpoint achieved with an impressive mean -14 point difference in Montgomery-Asberg Depression Rating Scale ("MADRS") score reduction from baseline betwe... Read More...

Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023

- Company to share topline Phase 2 safety and efficacy data for CYB003, its deuterated psilocybin analog being developed for the treatment of major depressive disorder -TORONTO, November 16, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to... Read More...

Cybin Announces Closing of Offering of Units Led by One of the Company’s Largest Institutional Shareholders

TORONTO, November 14, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that it has closed its previous... Read More...

Cybin Announces up to US$64 Million Offering of Units

TORONTO, November 10, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce a firm commitment underwritten ... Read More...

Cybin Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline

- Company to host conference call to discuss positive Phase 2 CYB003 interim results today, November 1, 2023 at 11:00 a.m. ET -- Complete Phase 2 topline data for CYB003 in MDD expected in Q4 2023 -TORONTO, November 01, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharma... Read More...

Cybin Announces Unprecedented Positive Interim Phase 2 Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose

- Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg Depression Rating Scale ("MADRS") score reduction from baseline between CYB003 (12mg) vs. placebo (p= 0.0005) -- For reference, pooled data from 232... Read More...

Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics

This news release constitutes a "designated news release" for the purposes of Cybin’s prospectus supplements each dated August 23, 2023, to its short form base shelf prospectus dated August 17, 2023.- Combined portfolios create the industry’s largest, most advanced, well-protected deuterated DMT program -- Combination creates the largest ... Read More...

Cybin Announces Date of Annual and Special Meeting of Shareholders

TORONTO, September 21, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that its 2023 Annual and Special Meeting of Sha... Read More...

Cybin Announces Overnight Marketed Public Offering of Units

TORONTO, July 31, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that it has launched an overnight marketed pu... Read More...

Cybin Announces Publication of Sponsored Feasibility Study Validating Kernel’s Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain

TORONTO, July 20, 2023--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, commends Kernel, a leader in non-invasive neuroimaging, on their pub... Read More...

Cybin Inc. Provides Corporate Update

- C$70M in potential funding through a combination of the previously announced common share purchase agreement and current "at-the-market" equity program helps support upcoming clinical milestones -- Topline clinical data readouts expected in late Q3 2023, including Phase 2a efficacy data for CYB003 and Phase 1 data for CYB004 -TORONTO, J... Read More...

Cybin Announces EMBARK Open Access, the First Free Online Course Providing Facilitator Training for Psychedelic Therapy

TORONTO, April 12, 2023--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced the launch of EMBARK Open Access ("EMBARK OA"), a f... Read More...

Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program

- CYB003 Phase 1/2a interim data demonstrate rapid and short-acting effects; robust psychedelic effects at low doses; positive safety and tolerability profile; top-line efficacy data expected late Q3 2023 -- Initial findings from Phase 1 CYB004-E study suggest IV DMT was well-tolerated; study design expanded to accelerate first-in-human d... Read More...

Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights

- Company to provide CYB003 Phase 1/2a interim study readout and update on its CYB004 program at upcoming R&D Day on February 28, 2023 -This news release constitutes a "designated news release" for the purposes of Cybin’s prospectus supplement dated August 8, 2022 to its short form base shelf prospectus dated July 5, 2021TORONTO, Febr... Read More...

Cybin Announces Promising Results from Sponsored Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

- Study supports earlier findings and demonstrates that Kernel Flow provides a functional measure of blood oxygenation changes in the brain associated with neural activity -TORONTO, January 18, 2023--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psyc... Read More...

Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004

TORONTO, January 12, 2023--(BUSINESS WIRE)--Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) (Cybin or the Company), a biotechnology company focused on progressing Psychedelics to Therapeutics® today announced that it has selected Generalized Anxiety Disorder ("GAD") with or without major depressive disorder ("MDD") as the target indication f... Read More...

Cybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

-- First-in-human Phase 1/2a trial evaluating the proprietary deuterated psilocybin analog CYB003 expected to begin in mid-2022 --TORONTO, June 09, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM", today announced... Read More...

Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy

TORONTO, June 02, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™", is pleased to announce the publication of a peer-reviewed article introducing EMBARK, a model of psychedelic-assisted psychotherapy that integra... Read More...

Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s Effects on the Brain

- Preliminary data confirm Flow's ability to successfully measure neuro-effect of ketamine over 10 days -- Results to be presented at PSYCH Symposium taking place in London on May 11, 2022 -LOS ANGELES & TORONTO, May 09, 2022--(BUSINESS WIRE)--Kernel, a leader in non-invasive neuroimaging, and Cybin Inc. (NEO:CYBN) (NYSE American:CYBN... Read More...

Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

TORONTO, April 21, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM", today announced that it has partnered with Clinilabs Drug Development Corporation ("Clinilabs"), a global, full-service contract research organiza... Read More...

Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT

- Delivery of CYB004 via inhalation showed significant advantages over intravenously administered dimethyltryptamine ("IV DMT") in preclinical studies --- Rapid onset, longer duration of action and similar low variability achieved with single inhalation of CYB004 compared with IV DMT –- Inhaled CYB004 demonstrated more than 40% improved b... Read More...

Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

TORONTO, March 31, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM", today announced that the first study visit has been conducted in a Cybin-sponsored feasibility study evaluating Kernel’s quantitative neuroimaging... Read More...

Cybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting Participants

TORONTO, March 24, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™", reports that its Company-sponsored feasibility study using Kernel’s quantitative neuroimaging technology, Kernel Flow, is actively recruiting p... Read More...

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leads Out in Psychedelic-Based Therapeutics Space

NEW YORK, March 07, 2022 -- NetworkNewsAudio – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) announces the availability of a broadcast titled, “Psychedelic Therapies Offer Hope for Mental Health.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/JeGwq Th... Read More...

Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain

-Enrollment expected to begin in early 2022 - TORONTO, January 11, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™", today announced that an Institutional Review Board ("IRB") has approved a Company-sponsored feasibility study us... Read More...

Cybin Provides 2021 Year End Summary

TORONTO, December 22, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™" is pleased to provide a year-end summary of its major milestones and key catalysts from 2021 that it believes have positioned the Company for... Read More...